title: Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.
abstract: The in vitro activity of aztreonam and 10 other antibiotics was determined for clinical isolates of Pseudomonas aeruginosa from 18 cystic fibrosis patients obtained before, at the end of, and 7-14 days after the completion of therapy with aztreonam. The percent of isolates susceptible to aztreonam at each sampling period were 79%, 78%, and 81% respectively.
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001398:Aztreonam / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications*; D004352:Drug Resistance, Microbial; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000900:Anti-Bacterial Agents; D001398:Aztreonam